<DOC>
	<DOCNO>NCT01446744</DOCNO>
	<brief_summary>Stereotactic Ablative Radiotherapy ( SABR ) new radiation treatment delivers high-dose , precise radiation small tumor 1-3 week treatment . This new technique potentially allow radiation treatment focus precisely , deliver accurately old treatment . This improvement could help reduce side effect improve chance control cancer precisely treat cancer . The purpose study compare SABR current approach chemotherapy conventional radiotherapy assess impact overall survival quality life .</brief_summary>
	<brief_title>Stereotactic Ablative Radiotherapy Comprehensive Treatment Oligometastatic Tumors ( SABR-COMET )</brief_title>
	<detailed_description>TREATMENT PLAN 6.0.1 Standard Arm ( Arm 1 ) Radiotherapy patient standard arm follow principle palliative radiotherapy per individual institution , goal alleviate symptom prevent imminent complication . Patients arm receive stereotactic dos radiotherapy boost . Treatment recommendation follow : Brain : Whole brain radiotherapy i.e . 20 Gy 5 fraction , 30 Gy 10 fraction Lung : Palliative radiotherapy per 2011 consensus guidelines.15 i.e . 8 Gy 1 fraction , 20 Gy 5 fraction , 30 Gy 10 fraction Bone : Palliative radiotherapy per 2011 consensus guidelines.16 i.e . 8 Gy 1 fraction ( common ) , 20 Gy 5 fraction , 30 Gy 10 fraction Liver : 20 Gy 5 fraction standard institutional practice 6.0.2 Treatment Planning Standard Arm Treatment plan do use CT simulation conventional simulation ( fluoroscopy ) per individual institutional practice . Simple beam arrangement , parallel oppose beam , favor wherever possible . 6.1 Experimental Arm ( Arm 2 ) All treatment study base current protocol clinical use LRCP VUmc treatment lung,17 liver,18 brain,19,20 spinal cord21 metastasis . The guide principle radiotherapy achieve disease control minimize potential adverse impact quality life . Concurrent chemotherapy target therapy time radiotherapy permit within 4 week prior SABR . Hormone therapy permit . 6.1.1 Dose/Fractionation Lung- tumor 3 cm less surrounded lung parenchyma , 54 ( Gy ) 3 fraction - Abutting chest wall &gt; 3 cm , 55 ( Gy ) 5 fraction , every second day - Within 2 cm mediastinum brachial plexus , 60 ( Gy ) ,8* fraction , every second day Bone -Any bone except femur,35 ( Gy ) , 5 fraction , daily - vertebral body,16-20 ( Gy ) 1 fraction , single dose , 30Gy 3 fraction , every second day Brain - Non-radiosurgical,40 ( Gy ) metastases , 5 fraction , daily - If whole brain treat , simultaneous boost lesion,20 Gy whole brain ( optional ) , 5 fraction , daily - Radiosurgical , ≤1 cm , 22-24 ( Gy ) , 1 fraction , &gt; 1 ≤2 cm , 22-24 ( Gy ) 1 fraction &gt; 2 ≤ 3 cm , 18-20 ( Gy ) 1 fraction Optional whole brain follow ( see text ) Liver-LRCP site : Dose base calculate normal tissue probability &lt; 5 % , Every second day - sit 45-60 ( Gy ) , 3-8 fraction , every second day Adrenal , 60 ( Gy ) , 8 fraction , every second day ( If whole brain treat , simultaneous boost lesion ) 6.1.2 Immobilization Treatment setup use reproducible positioning , verify use on-line protocol , patient study . Immobilization may include custom immobilization device , thermoplastic shell vac-lok bag , per individual institutional practice deliver SABR . Some center use immobilization device demonstrate high degree accuracy ; acceptable study . 6.1.3 Imaging/Localization/Registration All patient Arm 2 undergo planning CT simulation . 4-dimensional CT use tumor lung liver . Axial CT image obtain throughout region interest . For centre use stereotactic radiosurgery platform , real-time tumor track orthogonal image system permit . Any center yet experienced lesion specific sub-site ( e.g . adrenal metastasis ) shall eligible participate include patient lesion pre-specified site It strongly recommend dos organ risk exceed - specific case , may require low dos high fractionation list . Such change dose require approval one local principal investigator . ( see section 6.2 )</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Age 18 old Willing provide inform consent Histologically confirm malignancy metastatic disease detect image . Biopsy metastasis prefer , require . ECOG performance status 01 Controlled primary tumor a. define : least 3 month since original tumor treat definitively , progression primary site All sit disease safely treat base criterion Maximum 3 metastasis single organ system ( i.e . lung , liver , brain , bone ) Life expectancy &gt; 6 month Not candidate surgical resection site : surgery sit recommend multidisciplinary team , unfit decline surgery Prior chemotherapy allow systemic therapy 4 week prior first fraction radiotherapy , radiotherapy , two week last fraction Patients metastases previously treat ( e.g . prior resection , Radiofrequency Ablation ( RFA ) radiotherapy ) : . If previously treat metastasis control imaging , patient eligible study site need treatment . If previously treat metastasis NOT control imaging : 1 . If previous treatment surgery , patient eligible site treat SABR 2 . If previous treatment radiotherapy RFA , patient ineligible . Patient present multidisciplinary tumor board qualityassurance round . Serious medical comorbidities preclude radiotherapy Bone metastasis femoral bone Patients 13 brain metastasis disease elsewhere ( patient randomize treated stereotactic radiotherapy per result randomized trial ) Prior radiotherapy site require treatment Complete response firstline chemotherapy ( i.e . measurable target SABR ) Malignant pleural effusion Inability treat site active disease Clinical radiologic evidence spinal cord compression OR tumor within 3 mm spinal cord Magnetic Resonance Imaging ( MRI ) . Dominant brain metastasis require surgical decompression Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>